Options to optimize the access to biosimilars: analysis and solutions
The cost of medical care has been growing around the world; this is due to a number of factors, including the growing use of costly medicines for cancer and rare (orphan) diseases. The introduction of reproduced medicinal products instead of original ones opens the way to medical cost reduction. In...
Saved in:
| Main Authors: | O. V. Kirsanova, V. V. Omelyanovsky |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2018-05-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/230 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW
by: D. G. Tolkacheva, et al.
Published: (2018-02-01) -
Biosimilars - drugs of the future
by: E. A. Eltcova, et al.
Published: (2014-04-01) -
BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01) -
Approaches to resolve practical challenges in the context of assessing the price of biosimilar products
by: A. H.-M. Valeeva, et al.
Published: (2025-01-01) -
Lo que debe saber el dermatólogo sobre los medicamentos biológicos y los biosimilares
by: Gloria Sanclemente
Published: (2019-03-01)